Market closed
Adverum Biotechnologies/$ADVM
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Adverum Biotechnologies
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.
Ticker
$ADVM
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
121
Website
ADVM Metrics
BasicAdvanced
$98M
Market cap
-
P/E ratio
-$5.51
EPS
1.01
Beta
-
Dividend rate
Price and volume
Market cap
$98M
Beta
1.01
52-week high
$29.70
52-week low
$4.66
Average daily volume
263K
Financial strength
Current ratio
5.824
Quick ratio
5.541
Long term debt to equity
43.439
Total debt to equity
50.836
Management effectiveness
Return on assets (TTM)
-29.83%
Return on equity (TTM)
-76.26%
Valuation
Price to revenue (TTM)
80.308
Price to book
0.68
Price to tangible book (TTM)
0.68
Price to free cash flow (TTM)
-0.933
Growth
Revenue change (TTM)
-72.22%
Earnings per share change (TTM)
-56.13%
3-year revenue growth (CAGR)
-48.91%
3-year earnings per share growth (CAGR)
-28.71%
What the Analysts think about ADVM
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Adverum Biotechnologies stock.
ADVM Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ADVM Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
ADVM News
AllArticlesVideos
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·2 weeks ago
Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·1 month ago
Adverum: Ixo-Vec Could Reduce Treatment Burden For Wet-AMD Patients
Seeking Alpha·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Adverum Biotechnologies stock?
Adverum Biotechnologies (ADVM) has a market cap of $98M as of December 21, 2024.
What is the P/E ratio for Adverum Biotechnologies stock?
The price to earnings (P/E) ratio for Adverum Biotechnologies (ADVM) stock is 0 as of December 21, 2024.
Does Adverum Biotechnologies stock pay dividends?
No, Adverum Biotechnologies (ADVM) stock does not pay dividends to its shareholders as of December 21, 2024.
When is the next Adverum Biotechnologies dividend payment date?
Adverum Biotechnologies (ADVM) stock does not pay dividends to its shareholders.
What is the beta indicator for Adverum Biotechnologies?
Adverum Biotechnologies (ADVM) has a beta rating of 1.01. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.